Study makes case for treating all dangerous lesions in PCI for STEMI | Biodegradable DES performs as well as standard device, research finds | STEMI patients don't benefit from thrombus aspiration before PCI, study finds
Web Version
 
September 9, 2014
SCAI SmartBrief
News for Invasive/Interventional Cardiologists
SIGN UP|FORWARD|ARCHIVE|ADVERTISE

Top Stories
Study makes case for treating all dangerous lesions in PCI for STEMI
Research presented at the European Society of Cardiology meeting provides evidence for treating all threatening lesions, not just the culprit lesion, when STEMI patients undergo PCI. Meta-analyses and retrospective registry data indicate patient outcomes were enhanced with the more extensive approach, although questions about clinical decision making remain, said Dr. Anthony Gershlick. The CvLPRIT study found a 55% drop in major adverse cardiovascular event incidence when the nonculprit artery is treated, Gershlick said. "We saw no adverse safety signal," he added. MedPage Today (free registration) (9/2)
Share: LinkedInTwitterFacebookGoogle+Email
Biodegradable DES performs as well as standard device, research finds
A new biodegradable polymer sirolimus-eluting stent performed as well as a durable everolimus-eluting polymer device, according to a study presented at the European Society of Cardiology meeting. The study didn't involve high-risk patients, but those with stable coronary artery disease or acute coronary syndrome were eligible, and many lesions were complex. "Our findings document excellent clinical outcomes for both stent types in a patient population with minimal exclusion criteria," the authors wrote. CardiovascularBusiness.com (9/2)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Policy & Professional News
Survey looks at trends in cardiology pay, volume
The median salary for cardiologists fell 8% between 2012 and 2013, according to data from MedAxiom, with specialty and practice type playing a role. The study also noted changes in procedural volume, something SCAI fellow Dr. Thomas Tu said is driven in part by pharmacological and technological advances. Tu said precision in care delivery is also a factor, but efforts to ensure appropriate treatment must be handled with care. "Forcing physicians to be more careful in their judgment can help patients," he said. "But at the same time, it has to be balanced with the fear of restricting access to reasonable care." MedPage Today (free registration) (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
CMS to add CABG in next round of readmission penalties
The second round of CMS readmission penalties will add coronary artery bypass graft surgery as a reportable event in fiscal 2017, but instead of focusing on discharges, CMS plans to look at the hospital involved with the initial admission. Dr. Todd Rosengart at the Baylor College of Medicine said CABG is a good measure to include because there is so much data on it and it is a high-volume procedure that has an economic impact. CardiovascularBusiness.com (9/2)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Medical Developments
Study: Colchicine may be risky for heart surgery patients
Data on 360 heart surgery patients in Italy showed colchicine intake helped reduce the risk of postpericardiotomy syndrome, but it failed to reduce the odds of other postsurgical complications including atrial fibrillation and pericardial or pleural effusion compared with placebo. Colchicine users were also more likely to experience nausea and gastrointestinal problems such as diarrhea and abdominal pain. The findings appear in the Journal of the American Medical Association. DailyRx.com (8/31)
Share: LinkedInTwitterFacebookGoogle+Email
Medtronic's next-gen heart valve gains approval in Europe
Medtronic has received CE mark approval to market its CoreValve Evolut R system in Europe. The next-generation transcatheter aortic valve implant is designed to promote optimal device placement by enabling surgeons to recapture and redeploy the valve to its ideal position as needed. MassDevice.com (Boston) (9/3)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
SCAI News
SCAI 2015 calls for abstract submissions
Want your research published in interventional cardiology's leading journal, Catheterization & Cardiovascular Interventions? Then be sure to submit your abstract(s) to SCAI 2015 Scientific Sessions, the best forum for your interventional and invasive cardiology research! In addition to being published in CCI, all accepted abstract presenters also receive free registration to SCAI 2015. Find out more and submit now.
Share: LinkedInTwitterFacebookGoogle+Email
Launch your career with SCAI's Emerging Leader Mentorship program
Opportunities like this only come every two years! Interested in becoming a future leader in interventional cardiology? Be sure to participate in SCAI's Emerging Leader Mentorship Program, in formal partnership with the American College of Cardiology and the Cardiovascular Research Foundation. Don't delay -- ELM is now accepting applications for the 2015-17 ELM program. Apply now.
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
I must govern the clock -- not be governed by it."
-- Golda Meir,
former Israeli prime minister
Share: LinkedInTwitterFacebookGoogle+Email
The news summaries appearing in SCAI SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI SmartBrief constitute the official opinion of SCAI.
The SCAI SmartBrief news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI SmartBrief may be directed to SmartBrief at scai@smartbrief.com.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Melissa Turner
Advertising:  Wynn Hansen
  P: 202.470.1149
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information